Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: A retrospective US claims database analysis

Journal of Medical Economics

Volumn 17, Issue 10, 2014, Pages 696-707

  Bergvall, Niklas ^a   Petrilla, Allison A ^b   Karkare, Swapna U ^b   Lahoz, Raquel ^a   Agashivala, Neetu ^a   Pradhan, Ashish ^a   Capkun, Gorana ^a   Makin, Charles ^b   McGuiness, Catherine Balderston ^b   Korn, Jonathan R ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b IQVIA   (United States)

Author keywords

Adherence; Fingolimod; Glatiramer acetate; Interferon; Multiple sclerosis; Natalizumab; Persistence

Indexed keywords

4 AMINOPYRIDINE; BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; BETA INTERFERON; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PEPTIDE; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; DEPRESSION; DYSLIPIDEMIA; FEMALE; HEADACHE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PARESTHESIA; PRESCRIPTION; RELAPSE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT WITHDRAWAL; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; DRUG ADMINISTRATION ROUTE; INSURANCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSURANCE CLAIM REVIEW; INTERFERON-BETA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES; PROPORTIONAL HAZARDS MODELS; PROPYLENE GLYCOLS; RETROSPECTIVE STUDIES; SPHINGOSINE; UNITED STATES; YOUNG ADULT;

EID: 84907294269     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.940422     Document Type: Article

References (45)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31
2. Rolak LA. Multiple sclerosis: it ?s not the disease you thought it was. Clin Med Res 2003;1:57-60
3. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010;9:520-32
4. National Multiple Sclerosis Society. MS prevalence. http://www.nationalmssociety.org/about-the-society/ms-prevalence/index.aspx. Accessed June 22, 2013
5. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
6. Piaton G, Williams A, Seilhean D, et al. Remyelination in multiple sclerosis. Prog Brain Res 2009;175:453-64
7. Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med 1997;29:101-6
8. Richards RG, Sampson FC , Beard SM, et al. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002;6:1-73
9. The I FNB Multiple Sclerosis Study Group, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis., I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, 1993, 43, 655-61.
10. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 19 96;39:285-94
11. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000;6: 255-66
12. Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med 2011;78:161-75
13. Thone J, Ell richmann G. Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits. Drug Healthc Patient Saf 2013;5:37-47
14. FDA. Natalizumab (marketed as Tysabri) Prescribing and Labeling information: latest label approved 20/01/2012. http:///www.accessdata.fda.gov/drugsatfda-docs/label/2012/125104s0576lbl.pdf. Accessed March 8, 2012
15. EMA. Tysabri summary of product characteristics. 2011. http://www.ema. europa.eu/docs/en-GB/document-library/EPAR--Product-Information/human/000603/WC500044686.pdf. Accessed March 8, 2012
16. Chun J, Hartung HP. Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis. Clin Neuropharmacol [Review] 2010;33:91-101
17. Flachenecker P, Rieckmann P. Early intervention in multiple sclerosis: better outcomes for patients and society? Drugs 2003;63:1525-33
18. Comi G. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin Ther 2009;31:1142-57
19. Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-6 1
20. Ivanova JI, Bergman RE, Birnbaum HG, et al. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J M ed Econ 2012;15:601-9
21. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
22. Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010;30:89-100
23. Oleen-Burkey MA, Dor A, Castelli-Haley J, et al. The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate. J Med Econ 2011;14: 739-47
24. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:69-77
25. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256:568-76
26. Halpern R, Agarwal S, Borton L, et al. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis. Adv Ther 2011;28: 761-75
27. Halpern R, Agarwal S, Dembek C, et al. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analy sis. Patient Prefer Adherence 2011;5:73-84
28. Portaccio E, Amato MP. Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs 2009;23:453-62
29. Wong J, Gomes T, Mamdani M, et al. Adherence to multiple sclerosis diseasemodifying therapies in Ontario is low. Can J Neurol Sci 2011;38:429-33
30. Clerico M,Barbero P,Contessa G,et al., Adherence to interferon-beta treatment and results of therapy switching, J Neurol Sci, 2007, 259, 104-8.
31. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306-9
32. Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler 2012;18:932-46
33. Agashiva la N, Wu N, Abouzaid S, et al. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol 2013;13:138
34. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
35. Kappos L, Radue EW, O ?Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
36. Collins W, Cohen J, O ?Connor P, et al. Long-term safety of oral fingolimod (FTY720) in relapsing multiple sclerosis: integrated analyses of phase 2 and 3 studies. Mult Scler [Abstract] 2010;16:S295
37. Ontaneda D, Hara-Cleaver C, Rudick RA, et al. Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci 2012;323:167-72
38. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: gu idelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9
39. Roos LL, Stranc L, James RC, et al. Complications, comorbidities, and mortality: improving classification and prediction. Health Serv Res 1997;32:229-38; discussion 39-42
40. D? Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 1993;32:382-7
41. Reynolds MW, Stephen R, Seaman C, et al. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ 2010;13:90-8
42. Rich SR, Coleman IC, Cook R, et al. Stepped-care approach to treating MS: a managed care treatment algorithm. J Manag Care Pharm 2004;10:S26-32
43. Menzin J, Caon C, Nichols C, et al. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 2013;19:S24-40
44. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumabassociated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870 -80
45. FDA. FDA Drug Safety Co mmunication: revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). 2011. http://www.fda.gov/drugs/drugsafety/ucm303192.htm. Accessed June 9, 2014